Daklinza daclatasvir regulatory update

FDA approved an NDA from Bristol-Myers Squibb for its Daklinza daclatasvir in combination with Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.) to treat HCV genotype 3 infection. On July 24, BMS said it expects to launch Daklinza within a week at a list price of $63,000 for a 12-week course. BMS already markets the HCV NS5A protein inhibitor in the EU and Japan. ...